Skip to content
OpenCapital
Get started

United Therapeutics UTHR Nebulized Tyvaso — Total revenues

Other product segments

Tyvaso DPI
$330.3M+9.2%
Orenitram
$135.6M+12.3%
Remodulin
$126.6M-8.4%
Unituxin
$53.6M-7.9%
Adcirca
$2.9M-51.7%

Similar metrics at other companies

Biogen logo
BIIBTYSABRI — Total Revenue
$441.5M+15.7%
Mannkind logo
MNKDCollaborations And Services Related To Tyvaso DPI — Cost Of Revenue
$10M-27.0%
Mannkind logo
MNKDTyvaso DPI — Percentage Of Royalty On Net Sales
10%0.0pp
Tarsus Pharmaceuticals, Inc. logo
TARSProduct sales, net — Total revenues
$145.39M+85.6%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Bristol-Myers Squibb logo
BMYSotyktu — Total Revenues
$69M+25.5%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's nebulized tyvaso — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's nebulized tyvaso — total revenues?
United Therapeutics (UTHR) reported nebulized tyvaso — total revenues of $127.2M in Q1 2026.
How has United Therapeutics's nebulized tyvaso — total revenues changed year-over-year?
United Therapeutics's nebulized tyvaso — total revenues decreased by 22.3% year-over-year, from $163.8M to $127.2M.
What is the long-term trend for United Therapeutics's nebulized tyvaso — total revenues?
Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — total revenues has grown at a -1.2% compound annual growth rate (CAGR), from $607.5M to $585.7M.
What does nebulized tyvaso — total revenues mean?
This metric represents the total gross sales generated from the specific nebulized formulation of the company's primary pulmonary arterial hypertension therapy. It reflects the market adoption and commercial performance of this specific delivery mechanism within the broader product portfolio. Tracking this revenue stream helps investors assess the growth trajectory and competitive positioning of the company's core drug franchise.